Malgorzata Calbecka
Torun, KP, Poland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Impact of genetic polymorphisms of drug transporters ABCB1 and ABCG2 and regulators of xenobiotic transport and metabolism PXR and CAR on clinical efficacy of dasatinib in chronic myeloid leukemia.
Journal: Frontiers in oncology
Published: May 25, 2022
Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium.
Journal: Leukemia & lymphoma
Published: November 21, 2019
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Journal: British journal of haematology
Published: September 25, 2018
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Journal: Leukemia
Published: January 07, 2016
The germline mutations of the CHEK2 gene are associated with an increased risk of polycythaemia vera.
Journal: British journal of haematology
Published: June 19, 2015
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
Journal: Blood cells, molecules & diseases
Published: January 24, 2015
Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Journal: Leukemia & lymphoma
Published: January 08, 2015
Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study.
Journal: Leukemia & lymphoma
Published: November 14, 2014
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: June 01, 2013
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials.
Journal: European journal of haematology
Published: March 18, 2013
A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations.
Journal: Haematologica
Published: November 08, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026